Respiratory Syncytial Virus: Current Progress in Vaccine Development
Open Access
Abstract
Respiratory syncytial virus (RSV) is the etiological agent for a serious lower respiratory tract disease responsible for close to 200,000 annual deaths worldwide. The first infection is generally most severe, while re-infections usually associate with a milder disease. This observation and the finding that re-infection risks are inversely associated with neutralizing antibody titers suggest that immune responses generated toward a first RSV exposure can significantly reduce morbidity and mortality throughout life. For more than half a century, researchers have endeavored to design a vaccine for RSV that can mimic or improve upon natural protective immunity without adverse events. The virus is herein described together with the hurdles that must be overcome to develop a vaccine and some current vaccine development approaches.Keywords
This publication has 111 references indexed in Scilit:
- Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligandsVaccine, 2012
- Sendai virus-based RSV vaccine protects African green monkeys from RSV infectionVaccine, 2012
- Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these yearsVirus Research, 2011
- The many faces of Th17 cellsCurrent Opinion in Immunology, 2011
- Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial VirusJournal of Molecular Biology, 2011
- Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysisThe Lancet, 2010
- Respiratory viruses and eosinophils: Exploring the connectionsAntiviral Research, 2009
- Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSVVaccine, 2009
- Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infectionsVaccine, 2008
- Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and BVaccine, 2007